Eton Pharmaceuticals stock edges higher after strong 2025 growth figures

Published on 09/19/2026 at 16:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eton Pharmaceuticals stock reflects an enterprise value of about USD 80 million as of September 19, 2026, based on recent private-comps data. The company posted roughly USD 3 million of EBITDA in fiscal year 2025, highlighting a still-early but growing rare disease portfolio.

ETON, US2976021046, Illustration mit AI erstellt.

Eton Pharmaceuticals stock (ISIN US2976021046) stands for a specialty pharma player focused on rare disease treatments, with recent valuation data as of September 19, 2026 pointing to an enterprise value of around USD 80 million and EBITDA of roughly USD 3 million in fiscal year 2025.

Rare disease portfolio underpins fundamentals

According to Multiples.vc on September 19, 2026, Eton Pharmaceuticals generated about USD 3 million of EBITDA on an enterprise value of approximately USD 80 million for fiscal year 2025, implying an enterprise value to EBITDA multiple near 26.7x.

The same overview notes that Eton Pharmaceuticals focuses on four commercial rare disease products: Alkindi Sprinkle for adrenocortical insufficiency, Carglumic Acid for hyperammonemia, Betaine Anhydrous for homocystinuria, and Nitisinone for hereditary tyrosinemia type 1, giving the stock exposure to niche but clinically important markets.

Valuation and growth metrics in context

In the private-comps data, Eton Pharmaceuticals is listed with revenue of roughly USD 1.6 billion and EBITDA of USD 3 million for fiscal year 2025, which implies an EBITDA margin of around 0.2 percent and signals that the business is still in an early scaling phase despite sizable top-line figures from its rare disease portfolio.

The same data set shows an enterprise value around USD 80 million versus USD 3 million of EBITDA, an EV to EBITDA ratio near 26.7x, and a revenue multiple that is effectively near zero because the enterprise value is small compared with the reported revenue base, highlighting that profitability rather than pure sales volume is likely the key driver for how the market values Eton Pharmaceuticals stock.

Stock perspective for investors

For investors, the combination of a roughly USD 80 million enterprise value as of September 19, 2026 and about USD 3 million of EBITDA in fiscal year 2025 points to a company where future margin expansion in rare disease products could have an outsized impact on Eton Pharmaceuticals stock once operating leverage improves.